Nephrada · IGAN · Germany · Patient advocate · captured by Dr. Sophie Laurent on 20 Jun 2026 · reviewed by Dr. Marcus Lindqvist on 24 Jun 2026
Verbatim as captured; never edited
Patient representatives consistently reported that fatigue and the emotional burden of uncertain prognosis are more important to them than proteinuria numbers, which they do not understand. Two of four groups said trial endpoints 'talk past patients'.
Human-approved by Dr. Marcus Lindqvist on 24 Jun 2026
Patient advocacy groups prioritise fatigue and prognostic uncertainty over proteinuria; current endpoints perceived as not patient-relevant. Supports adding a fatigue PRO to the registry protocol.
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 5 | 20% | 20.0 |
| Strategic alignment | 4 | 20% | 16.0 |
| Scientific importance | 3 | 15% | 9.0 |
| Urgency | 3 | 15% | 9.0 |
| Novelty | 4 | 10% | 8.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 3 | 5% | 3.0 |
| Total | High 77 | ||
| Time | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 14 Sept 2026, 07:15 UTC | Create | MTMei Tanaka | progress | In progress → Submitted | — | Integration |
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
Insight
Reviewed 24 Jun 2026 by Dr. Marcus Lindqvist
HEOR · Dr. Nikolai Petrov · due 15 Aug 2026 · Completed
RWE project · Dr. Nikolai Petrov · Blocked
30 Jul 2026 · Approved
Outcome
Decision · DEC-0004
Closure